FrancophonIA/ELRC3.0 huggingface dataset:
English: - Take the dose as soon as you remember and: - take the next dose of Eliquis at the usual time - then continue as normal.
Croatian: - Uzmite dozu čim se sjetite i: uzmite sljedeću dozu lijeka Eliquis u uobičajeno vrijeme nastavite uzimati lijek kao i dotad.
English: Apixaban is a potent, oral, reversible, direct and highly selective active site inhibitor of factor Xa.
Croatian: Apiksaban je snažan, reverzibilan, izravan i visokoselektivan inhibitor aktivnog mjesta faktora Xa za peroralnu primjenu.
English: Patients undergoing catheter ablation (NVAF) Patients can continue apixaban use while undergoing catheter ablation (see sections 4.3, 4.4 and 4.5).
Croatian: Bolesnici koji će biti podvrgnuti kateterskoj ablaciji (NVAF) Bolesnici mogu nastaviti s primjenom apiksabana dok su podvrgnuti kateterskoj ablaciji (vidjeti dijelove 4.3, 4.4 i 4.5).
English: Apixaban has no direct effects on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin.
Croatian: Apiksaban nema izravan učinak na agregaciju trombocita, ali neizravno inhibira agregaciju trombocita izazvanu trombinom.
English: In vitro apixaban studies showed no inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 or CYP3A4 (IC50 > 45 µM) and weak inhibitory effect on the activity of CYP2C19 (IC50 > 20 µM) at concentrations that are significantly greater than peak plasma concentrations observed in patients.
Croatian: Ispitivanja apiksabana in vitro pokazala su da on nema inhibicijski učinak na aktivnost CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 i CYP3A4 (IC50 > 45 µm) te da je slab inhibitor aktivnosti CYP2C19 (IC50 > 20 µm) pri koncentracijama koje su značajno više od vršne koncentracije lijeka u plazmi zabilježene u bolesnika.
English: Intake with food does not affect apixaban AUC or Cmax at the 10 mg dose.
Croatian: Uzimanje s hranom ne utječe na AUC ni Cmax apiksabana pri dozi od 10 mg.
English: The relationship between apixaban plasma concentration and anti-Factor Xa activity was best described by a linear model.
Croatian: Odnos između koncentracija apiksabana u plazmi i anti-FXa aktivnosti najbolje se opisuje linearnim modelom.
English: Eliquis should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding.
Croatian: Eliquis treba prestati primjenjivati barem 24 sata prije elektivnog kirurškog zahvata ili invazivnih postupaka kod kojih postoji malen rizik od krvarenja.
English: Anti-FXa activity exhibits a close direct linear relationship with apixaban plasma concentration, reaching maximum values at the time of apixaban peak plasma concentrations.
Croatian: Anti-FXa aktivnost blisko je i izravno linearno povezana s koncentracijama apiksabana u plazmi pa maksimalne vrijednosti doseže u vrijeme vršnih koncentracija apiksabana u plazmi.
English: Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy
Croatian: Hemodinamski nestabilni bolesnici s PE ili bolesnici kojima je potrebna tromboliza ili plućna embolektomija
English: Apixaban is not recommended during pregnancy.
Croatian: Ne preporučuje se koristiti apiksaban tijekom trudnoće.
English: Renal impairment had no evident effect on the relationship between apixaban plasma concentration and anti-FXa activity.
Croatian: Oštećenje bubrežne funkcije nije imalo primjetan učinak na odnos između koncentracije apiksabana u plazmi i anti-FXa aktivnosti.
English: Oral use Eliquis should be swallowed with water, with or without food.
Croatian: Za peroralnu primjenu Eliquis treba progutati s vodom, s hranom ili bez nje.
English: If cardioversion is required before 5 doses of apixaban can be administered, a 10 mg loading dose should be given, followed by 5 mg twice daily.
Croatian: Ako je kardioverziju nužno provesti prije nego što je moguće dati 5 doza apiksabana, potrebno je primijeniti udarnu dozu od 10 mg, a nakon toga dozu od 5 mg dvaput na dan.
English: Compared to apixaban exposure in subjects with body weight of 65 to 85 kg, body weight > 120 kg was associated with approximately 30% lower exposure and body weight < 50 kg was associated with approximately 30% higher exposure.
Croatian: U usporedbi s izloženosti apiksabanu ispitanika tjelesne težine od 65 do 85 kg, u ispitanika tjelesne težine > 120 kg primijećeno je smanjenje izloženosti za približno 30%, a u ispitanika tjelesne težine < 50 kg povećanje izloženosti za približno 30%.
English: ADVANCE-3 (hip)
Croatian: ADVANCE-3 (kuk)
English: Limited clinical data indicate that apixaban plasma concentrations are increased in patients with severe renal impairment (creatinine clearance 15-29 mL/min) which may lead to an increased bleeding risk.
Croatian: Ograničeni klinički podaci ukazuju na to da su koncentracije apiksabana u plazmi povišene u bolesnika s teškim oštećenjem bubrega (klirens kreatinina 15-29 ml/min), što može dovesti do povećanog rizika od krvarenja.
English: However, this may increase your risk of bleeding.
Croatian: Međutim, to može povisti rizik od krvarenja.
English: Gamma-glutamyltransferase increased
Croatian: Povišenje gama-glutamiltransferaze često često
English: Blood clots may break off and travel to the brain and lead to a stroke or to other organs and prevent normal blood flow to that organ (also known as a systemic embolism).
Croatian: Krvni ugrušci mogu se odvojiti i krvotokom doći u mozak te prouzročiti moždani udar ili u druge organe gdje mogu ometati normalan dotok krvi u taj organ (što se naziva i sistemskom embolijom).
English: AMPLIFY STUDY
Croatian: ISPITIVANJE AMPLIFY
English: Apixaban can be taken with or without food.
Croatian: Apiksaban se može uzimati s hranom ili bez nje.
English: In studies conducted in healthy subjects, as described below, apixaban did not meaningfully alter the pharmacokinetics of digoxin, naproxen, or atenolol.
Croatian: U ispitivanjima sa zdravim ispitanicima, opisanima u nastavku, apiksaban nije značajno izmijenio farmakokinetiku digoksina, naproksena ni atenolola.
English: Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) The clinical program (AMPLIFY: apixaban versus enoxaparin/warfarin, AMPLIFY-EXT: apixaban versus placebo) was designed to demonstrate the efficacy and safety of apixaban for the treatment of DVT and/or PE (AMPLIFY), and extended therapy for the prevention of recurrent DVT and/or PE following 6 to 12 months of anticoagulant treatment for DVT and/or PE (AMPLIFY-EXT).
Croatian: Liječenje DVT, liječenje PE i prevencija ponavljajućih DVT i PE (VTEt) Klinički program (AMPLIFY: apiksaban u odnosu na enoksaparin/varfarin, AMPLIFY-EXT: apiksaban u odnosu na placebo) osmišljen je kako bi pokazao djelotvornost i sigurnost apiksabana u liječenju DVT i/ili PE (AMPLIFY) i produljenoj terapiji u prevenciji ponavljajućih DVT i/ili PE nakon liječenja antikoagulansom za DVT i/ili PE (AMPLIFY-EXT) u trajanju od 6 do 12 mjeseci.
English: Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis.
Croatian: Prije neuroaksijalne intervencije liječnik mora razmotriti potencijalnu korist u odnosu na rizik u bolesnika koji uzimaju antikoagulanse ili u bolesnika koji će antikoagulantnu terapiju primati za profilaksu tromboze.
English: Eliquis (apixaban) is an oral anticoagulant acting by direct selective inhibition of factor Xa.
Croatian: • Eliquis (apiksaban) je oralni antikoagulans, koji djeluje izravnom selektivnom inhibicijom faktora Xa.
English: - Changing from treatment with anticoagulant containing vitamin K antagonist (e.g., warfarin) to Eliquis
Croatian: - Prelazak s liječenja antikoagulansom koji sadrži antagonist vitamina K (npr. varfarin) na Eliquis
English: In a study comparing 8 subjects with mild hepatic impairment, Child-Pugh A score 5 (n = 6) and score 6 (n = 2), and 8 subjects with moderate hepatic impairment, Child-Pugh B score 7 (n = 6) and score 8 (n = 2), to 16 healthy control subjects, the single-dose pharmacokinetics and pharmacodynamics of apixaban 5 mg were not altered in subjects with hepatic impairment.
Croatian: U ispitivanju u kojem je uspoređivano 8 ispitanika s blagim oštećenjem jetrene funkcije: Child-Pugh stadij A - 5 bodova (n = 6) i 6 bodova (n = 2) i 8 ispitanika s umjerenim oštećenjem jetrene funkcije: Child-Pugh stadij B - 7 bodova (n = 6) i 8 bodova (n = 2) sa 16 zdravih kontrolnih ispitanika, farmakokinetika i farmakodinamika jedne doze apiksabana od 5 mg nisu se promijenile u ispitanika s oštećenjem jetre.
English: • Guidance regarding switching from or to Eliquis treatment
Croatian: • Smjernice za prebacivanje na liječenje ili sa liječenja lijekom Eliquis
English: Carry this card with you at all times
Croatian: Ovu karticu uvijek nosite sa sobom
English: Apixaban exposure parameters exhibit low to moderate variability reflected by a within-subject and inter-subject variability of ~20% CV and ~30% CV, respectively.
Croatian: Parametri ekspozicije apiksabana iskazuju nisku do umjerenu varijabilnost koja se odražava u obliku intraindividualne varijabilnosti od ~20% CV te interindividualne varijabilnosti od ~30% CV.
English: The results across phase I studies showed no discernible difference in apixaban pharmacokinetics between White/Caucasian, Asian and Black/African American subjects.
Croatian: Rezultati svih ispitivanja faze I nisu pokazali primjetne razlike u farmakokinetici apiksabana između ispitanika bijele rase, ispitanika azijskoga podrijetla i ispitanika crne rase.
English: The pharmacodynamic effects of apixaban are reflective of the mechanism of action (FXa inhibition).
Croatian: Farmakodinamički učinci apiksabana održavaju njegov mehanizam djelovanja (inhibicija faktora Xa).
English: • The need to inform Health Care Professionals that they are taking Eliquis if they need to have any surgery or invasive procedure.
Croatian: • Potreba da bolesnik obavijesti liječnika da uzima Eliquis ako se mora podvrgnuti bilo kakvom kirurškom zahvatu ili invazivnom postupku.
English: Nonfatal PE†
Croatian: Nefatalni PE
English: It is not known if Eliquis passes into human breast milk.
Croatian: Nije poznato izlučuje li se Eliquis u majčino mlijeko.
English: Given the predictable, dose-proportional pharmacokinetic profile of apixaban, the bioavailability results from the conducted studies are applicable to lower apixaban doses.
Croatian: S obzirom na predvidljivi farmakokinetički profil apiksabana koji je proporcionalan dozi, rezultati bioraspoloživosti iz provedenih studija primjenjivi su za manje doze apiksabana.
English: • Rinse the pestle and mortar you used for crushing the tablet and the container, with a little water or one of the other liquids (e.g., 30 mL), and swallow the rinse.
Croatian: • Isperite tučak i mužar koji ste koristili za drobljenje tablete te posudu s malo vode ili jedne od drugih tekućina (npr. 30 ml) te progutajte tu tekućinu.
English: Care is to be taken if patients are treated concomitantly with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), or non-steroidal anti-inflammatory drugs (NSAIDs), including acetylsalicylic acid.
Croatian: Nužan je oprez ako se bolesnici istodobno liječe selektivnim inhibitorima ponovne pohrane serotonina (SSRI) ili inhibitorima ponovne pohrane serotonina i noradrenalina (SNRI) ili nesteroidnim protuupalnim lijekovima (NSAIL), uključujući acetilsalicilatnu kiselinu (ASK).
English: When neuraxial anaesthesia (spinal/epidural anaesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal haematoma which can result in long-term or permanent paralysis.
Croatian: Kad se u bolesnika liječenih antitromboticima za prevenciju tromboembolijskih komplikacija primjenjuje neuroaksijalna anestezija (spinalna/epiduralna anestezija) ili izvodi spinalna/epiduralna punkcija, postoji rizik od nastajanja epiduralnog ili spinalnog hematoma koji može prouzročiti dugotrajnu ili trajnu paralizu.
English: The ADVANCE-3 study included 5,407 patients undergoing elective hip replacement, and the ADVANCE-2 study included 3,057 patients undergoing elective knee replacement.
Croatian: Ispitivanje ADVANCE-3 obuhvatilo je 5407 bolesnika podvrgnutih elektivnom kirurškom zahvatu ugradnje endoproteze kuka, a ispitivanje ADVANCE-2 obuhvatilo je 3057 bolesnika podvrgnutih elektivnom kirurškom zahvatu ugradnje endoproteze koljena.
English: There is no clinical experience with the use of apixaban with indwelling intrathecal or epidural catheters.
Croatian: Nema kliničkog iskustva s primjenom apiksabana u kombinaciji s trajnim intratekalnim ili epiduralnim kateterima.
English: Efficacy and safety of apixaban in the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) in patients with active cancer have not been established.
Croatian: Djelotvornost i sigurnost apiksabana u liječenju DVT, liječenju PE i prevenciji ponavljajućih DVT i PE (VTEt) u bolesnika s aktivnim rakom nisu ustanovljene.
English: Available data in animals have shown excretion of apixaban in milk.
Croatian: Dostupni podaci u životinja ukazuju da se apiksaban izlučuje u majčino mlijeko.
English: • Guidance regarding surgery or invasive procedure, and temporary discontinuation
Croatian: • Smjernice u slučaju kirurških zahvata ili invazivnih postupaka te privremenog prekida liječenja
English: Do not stop taking Eliquis without talking to your doctor first, because the risk of developing a blood clot could be higher if you stop treatment too early.
Croatian: Nemojte prestati uzimati Eliquis ako prethodno o tome niste razgovarali sa svojim liječnikom zbog mogućeg povišenja rizika od nastanka krvnog ugruška u slučaju preranog prekidanja liječenja.
English: • Importance of treatment compliance
Croatian: • Važnost pridržavanja plana liječenja
English: Eliquis should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of bleeding.
Croatian: Eliquis treba prestati primjenjivati barem 48 sati prije elektivnog kirurškog zahvata ili invazivnih postupaka kod kojih postoji umjeren ili visok rizik od krvarenja.
English: - Changing from Eliquis to anticoagulant medicines Stop taking Eliquis.
Croatian: - Prelazak s lijeka Eliquis na antikoagulanse Prestanite uzimati Eliquis.
English: The duration of overall therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding (see section 4.4).
Croatian: Potrebno je prilagoditi trajanje ukupne terapije stvarnim potrebama individualnog bolesnika nakon pažljive procjene koristi liječenja i rizika od krvarenja (vidjeti dio 4.4).
English: In patients with severe renal impairment (creatinine clearance 15-29 mL/min) the following recommendations apply (see sections 4.4 and 5.2):
Croatian: U bolesnika s teškim oštećenjem bubrežne funkcije (klirens kreatinina 15-29 ml/min) primjenjuju se sljedeće preporuke (vidjeti dijelove 4.4 i 5.2):
English: Coadministration of apixaban (20 mg once a day) and digoxin (0.25 mg once a day), a P-gp substrate, did not affect digoxin AUC or Cmax.
Croatian: Istodobna primjena apiksabana (20 mg jedanput na dan) i digoksina (0,25 mg jedanput na dan), supstrata P-gp-a, nije utjecala na AUC ni Cmax digoksina.
English: Eliquis administration should be discontinued if severe haemorrhage occurs (see sections 4.8 and 4.9).
Croatian: Primjena lijeka Eliquis mora se prekinuti ako nastupi ozbiljno krvarenje (vidjeti dijelove 4.8 i 4.9).
English: Renal excretion of apixaban accounts for approximately 27% of total clearance.
Croatian: Izlučivanje apiksabana putem bubrega čini otprilike 27% ukupnog klirensa.
English: For patients not previously treated with anticoagulants, exclusion of left atrial thrombus using an image guided approach (e.g. transesophogeal echocardiography (TEE) or computed tomographic scan (CT)) prior to cardioversion should be considered, in accordance with established medical guidelines.
Croatian: U bolesnika koji prethodno nisu bili liječeni antikoagulansima potrebno je prije kardioverzije razmotriti primjenu pristupa vođenog slikom (npr. transezofagealna ehokardiografija ili slika kompjutorizirane tomografije) radi isključenja tromba u lijevom atriju, u skladu s važećim medicinskim smjernicama.
English: Interaction with other medicinal products affecting haemostasis Due to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated (see section 4.3).
Croatian: Interakcije s drugim lijekovima koji utječu na hemostazu Zbog povećanog rizika od krvarenja, istodobno liječenje bilo kojim drugim antikoagulansom je kontraindicirano (vidjeti dio 4.3).
English: Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) The recommended dose of apixaban for the treatment of acute DVT and treatment of PE is 10 mg taken orally twice daily for the first 7 days followed by 5 mg taken orally twice daily.
Croatian: Liječenje DVT, liječenje PE i prevencija ponavljajućih DVT i PE (VTEt) Preporučena doza apiksabana u liječenju akutne DVT i u liječenju PE je 10 mg peroralno dvaput na dan tijekom prvih 7 dana, nakon čega slijedi 5 mg peroralno dvaput na dan.
English: In the thrombin generation assay, apixaban reduced endogenous thrombin potential, a measure of thrombin generation in human plasma.
Croatian: U testu stvaranja trombina, apiksaban je smanjio potencijal endogenog trombina, mjeru stvaranja trombina u ljudskoj plazmi.
English: 14 film-coated tablets 20 film-coated tablets 28 film-coated tablets 56 film-coated tablets 60 film-coated tablets 100x 1 film-coated tablets 168 film-coated tablets 200 film-coated tablets
Croatian: 14 filmom obloženih tableta 20 filmom obloženih tableta 28 filmom obloženih tableta 56 filmom obloženih tableta 60 filmom obloženih tableta 100 x 1 filmom obložena tableta 168 filmom obloženih tableta 200 filmom obloženih tableta
English: Common adverse reactions were haemorrhage, contusion, epistaxis, and haematoma (see Table 2 for adverse reaction profile and frequencies by indication).
Croatian: Česte nuspojave bile su krvarenje, kontuzija, epistaksa i hematom (vidjeti Tablicu 2 za profil nuspojava i učestalosti po indikaciji).
English: Table 1:
Croatian: Tablica 1
English: Gender No dose adjustment required (see section 5.2).
Croatian: Spol Nije potrebno prilagođavati dozu (vidjeti dio 5.2).
English: Body weight Low body weight (< 60 kg) may increase haemorrhagic risk (see section 5.2).
Croatian: Niska tjelesna težina (< 60 kg) može povisiti rizik od krvarenja (vidjeti dio 5.2).
English: If you have had a major hip operation you will usually take the tablets for 32 to38 days If you have had a major knee operation you will usually take the tablets for 10 to 14 days
Croatian: Ako ste imali veliku operaciju na kuku, tablete ćete obično uzimati 32 do 38 dana.
English: There was an increase in apixaban exposure correlated to decrease in renal function, as assessed via measured creatinine clearance.
Croatian: Zabilježeno je povećanje izloženosti apiksabanu koje je u korelaciji sa smanjenjem bubrežne funkcije, što je utvrđeno mjerenjem klirensa kreatinina.
English: The tablet may be crushed and mixed with water, or 5% dextrose in water, or apple juice or apple puree, immediately before you take it.
Croatian: Tableta se može zdrobiti i pomiješati s vodom ili 5%-tnom otopinom glukoze u vodi ili sa sokom od jabuke ili s pireom od jabuke neposredno prije uzimanja.
English: 10 film-coated tablets 20 film-coated tablets 60 film-coated tablets 60 x 1 film-coated tablets 100 x 1 film-coated tablets 168 film-coated tablets 200 film-coated tablets
Croatian: 10 filmom obloženih tableta 20 filmom obloženih tableta 60 filmom obloženih tableta 60 x 1 filmom obložena tableta 100 x 1 filmom obložena tableta 168 filmom obloženih tableta 200 filmom obloženih tableta
English: The relationship between apixaban plasma concentration and anti-FXa activity is approximately linear over a wide dose range of apixaban.
Croatian: Povezanost između koncentracije apiksabana u plazmi i anti-FXa aktivnosti je približno linearna u širokom rasponu doza apiksabana.
English: In controlled clinical trials, orally-administered apixaban in healthy subjects at doses up to 50 mg daily for 3 to 7 days (25 mg twice daily (bid) for 7 days or 50 mg once daily (od) for 3 days) had no clinically relevant adverse effects.
Croatian: U kontroliranim kliničkim ispitivanjima apiksaban primijenjivan peroralno zdravim ispitanicima u dozama do 50 mg na dan tijekom 3 do 7 dana (25 mg dvaput na dan tijekom 7 dana ili 50 mg jedanput na dan tijekom 3 dana) nije izazvao klinički značajne nuspojave.
English: Plasma protein binding in humans is approximately 87%.
Croatian: U ljudi se približno 87% apiksabana veže se za proteine u plazmi.
English: - The need to inform Health Care Professionals that they are taking Eliquis if they need to have any surgery or invasive procedure.
Croatian: - Potrebi da obavijeste liječnika da uzimaju Eliquis ako se moraju podvrgnuti bilo kakvom kirurškom zahvatu ili invazivnom postupku.
English: Renal impairment In patients with mild or moderate renal impairment, the following recommendations apply:
Croatian: Oštećenje bubrežne funkcije U bolesnika s blagim ili umjerenim oštećenjem bubrežne funkcije primjenjuju se sljedeće preporuke:
English: - for the treatment of DVT and treatment of PE, apixaban should not be used since efficacy may be compromised.
Croatian: - u liječenju DVT i liječenju PE apiksaban se ne smije primjenjivati jer se može ugroziti djelotvornost.
English: The mean age was 56.7 years and 91.7% of randomised patients had unprovoked VTE events.
Croatian: Prosječna dob bila je 56,7 godina i 91,7% randomiziranih bolesnika imalo je neizazvane VTE.
English: Key Elements of the Patient Alert Card:
Croatian: Ključne informacije u Kartici s upozorenjima za bolesnika:
English: In a clinical study in atrial fibrillation patients, diminished efficacy and a higher risk of bleeding were observed with coadministration of apixaban with strong inducers of both CYP3A4 and P-gp compared with using apixaban alone.
Croatian: U kliničkom ispitivanju u bolesnika s fibrilacijom atrija uočena je smanjena djelotvornost i povećan rizik od krvarenja kod istodobne primjene apiksabana i snažnih induktora CYP3A4 i P-gp-a u usporedbi s primjenom samo apiksabana.
English: Alanine aminotransferase increased
Croatian: Povišenje alanin aminotransferaze manje često često
English: The initiation of appropriate treatment, e.g., surgical haemostasis, the transfusion of fresh frozen plasma or the administration of a reversal agent for factor Xa inhibitors should be considered.
Croatian: Treba razmotriti uvođenje odgovarajuće terapije, npr. kirurške hemostaze, transfuzije smrznute svježe plazme ili primjene lijeka za reverziju učinka inhibitora faktora Xa.
English: * Noninferior compared to enoxaparin/warfarin (p-value < 0.0001)
Croatian: * Neinferiorno u usporedbi s enoksaparinom/varfarinom (p-vrijednost <0,0001)
English: Especially, if you are older than 75 years and are taking acetylsalicylic acid, you may have an increased chance of bleeding.
Croatian: Povećan rizik od krvarenja postoji osobito ako ste stariji od 75 godina i uzimate acetilsalicilatnu kiselinu.
English: The following side effects are known if you take Eliquis to treat or prevent re-occurrence of blood clots in the veins of your legs and blood clots in the blood vessels of your lungs.
Croatian: Sljedeće nuspojave mogu nastupiti ako Eliquis uzimate za liječenje ili sprječavanje ponovnog nastanka krvnih ugrušaka u venama nogu i krvnih ugrušaka u krvnim žilama pluća.
English: Eliquis is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 4.3).
Croatian: Eliquis je kontraindiciran u bolesnika s bolešću jetre udruženom s koagulopatijom i klinički značajnim rizikom od krvarenja (vidjeti dio 4.3).